0000914121-16-001122.txt : 20160420 0000914121-16-001122.hdr.sgml : 20160420 20160420085038 ACCESSION NUMBER: 0000914121-16-001122 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160418 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20160420 DATE AS OF CHANGE: 20160420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC CENTRAL INDEX KEY: 0001275187 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113146460 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50761 FILM NUMBER: 161580436 BUSINESS ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 BUSINESS PHONE: 5187981215 MAIL ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 8-K 1 an35269091-8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):  April 18, 2016

AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
000-50761
11-3146460
(State or Other Jurisdiction
of Incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)
 
14 Plaza Drive Latham, New York
12110
(Address of Principal Executive Offices)
(Zip Code)
 
(518) 795-1400
(Registrant’s telephone number, including area code)
 
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 
Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 18, 2016, Michael Trimarchi, Vice President and Interim Chief Financial Officer of AngioDynamics, Inc. (the “Company” or “AngioDynamics”), notified the Company that he is resigning, and has accepted the position of Chief Accounting Officer at CommerceHub, a local, cloud-based technologies and services firm.  Mr. Trimarchi will remain with the Company until May 13, 2016 and assist in the Company’s continued efforts to identify a new CFO.  Mr. Trimarchi will not receive any severance or termination payments from the Company in connection with his resignation.

On April 18, 2016, the Company eliminated the position of Executive Vice President and Chief Commercial Officer, held by John Soto, effective May 2, 2016.  In consideration for a waiver and general release of claims executed by Mr. Soto in favor of the Company, Mr. Soto will receive severance payments equal to continuation of his annual base salary for a period of 12 months plus earned but unused vacation time.  AngioDynamics does not currently have plans to replace Mr. Soto or his position, as the Company will realign its reporting structure with direct oversight of the commercial organization by the Chief Executive Officer, James C. Clemmer.

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ANGIODYNAMICS, INC.  
    (Registrant)  
       
Date: April 20, 2016
By:
/s/ Stephen A. Trowbridge  
    Stephen A. Trowbridge  
    Senior Vice President and General Counsel